SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-598
|
$84.97
|
-$50.81K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-277
|
$86.81
|
-$24.05K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-598
|
$75.77
|
-$45.31K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-3.7K
|
$67.94
|
-$251.79K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-4.1K
|
$69.57
|
-$286.28K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1.3K
|
$68.36
|
-$91.60K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-983
|
$68.36
|
-$67.20K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1.2K
|
$69.86
|
-$83.27K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-1.2K
|
$69.86
|
-$82.23K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-15K
|
$68.47
|
-$1.02M
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-11K
|
$68.15
|
-$743.04K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-8.6K
|
$68.15
|
-$587.25K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-599
|
$68.61
|
-$41.10K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-1.8K
|
$68.00
|
-$122.06K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-20K
|
$67.69
|
-$1.34M
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-599
|
$69.99
|
-$41.92K
|
|
SEC
|
Denton Sheila A.
|
EVP & General Counsel
|
|
-14K
|
$74.07
|
-$1.04M
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-12K
|
$72.69
|
-$897.87K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-1.3K
|
$69.97
|
-$90.96K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-6K
|
$75.38
|
-$455.52K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-3.7K
|
$79.68
|
-$293.22K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-954
|
$63.11
|
-$60.21K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-8.5K
|
$62.36
|
-$526.94K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-12K
|
$60.63
|
-$703.79K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-16K
|
$70.00
|
-$1.09M
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1.3K
|
$64.19
|
-$83.83K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-8.1K
|
$60.00
|
-$488.88K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-19K
|
$60.00
|
-$1.15M
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-1.1K
|
$58.91
|
-$64.39K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-7.4K
|
$65.51
|
-$482.48K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-657
|
$65.00
|
-$42.71K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-1.3K
|
$61.55
|
-$78.60K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-8.4K
|
$65.13
|
-$550.28K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-22K
|
$63.28
|
-$1.36M
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
-1.2K
|
$80.08
|
-$94.41K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-2.4K
|
$85.00
|
-$205.62K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-105
|
$83.88
|
-$8.81K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-174
|
$81.26
|
-$14.14K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-174
|
$81.26
|
-$14.14K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-117
|
$79.08
|
-$9.25K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-117
|
$79.08
|
-$9.25K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-28K
|
$79.78
|
-$2.27M
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+294
|
$80.32
|
+$23.61K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+252
|
$80.32
|
+$20.24K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+302
|
$80.32
|
+$24.26K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-2.5K
|
$76.21
|
-$187.32K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-1.2K
|
$82.16
|
-$100.48K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+165
|
$69.59
|
+$11.48K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+339
|
$66.64
|
+$22.59K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+291
|
$66.64
|
+$19.39K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+250
|
$66.64
|
+$16.66K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
-1.6K
|
$83.13
|
-$130.02K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-2.9K
|
$79.38
|
-$228.06K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
-12K
|
$79.38
|
-$918.74K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
+9.1K
|
$12.85
|
+$116.85K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+10K
|
$16.31
|
+$163.48K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+39K
|
$20.56
|
+$807.17K
|
|
SEC
|
Iyengar Vijay K
|
EVP, GMAPPS
|
|
+15K
|
$16.45
|
+$240.89K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+21K
|
$14.55
|
+$305.14K
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
+16K
|
$4.83
|
+$78.21K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
+15K
|
$13.40
|
+$202.14K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+7.3K
|
$16.45
|
+$120.45K
|
|
SEC
|
Tray Thomas
|
Principal Accounting Officer
|
|
+3.2K
|
$15.23
|
+$48.16K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+321
|
$75.97
|
+$24.39K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+275
|
$75.97
|
+$20.89K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+236
|
$75.97
|
+$17.93K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-11K
|
$75.63
|
-$868.84K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-517
|
$80.95
|
-$41.85K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-2.1K
|
$77.15
|
-$164.25K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+326
|
$79.42
|
+$25.89K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+249
|
$79.42
|
+$19.78K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+280
|
$79.42
|
+$22.24K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+240
|
$79.42
|
+$19.06K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+429K
|
$67.56
|
+$28.99M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+526K
|
$67.96
|
+$35.73M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+1.6M
|
$66.91
|
+$106.95M
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
-1.2K
|
$66.76
|
-$78.58K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-7.4K
|
$74.19
|
-$547.15K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-78
|
$75.34
|
-$5.88K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-78
|
$75.34
|
-$5.88K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
+6.8K
|
$2.12
|
+$14.32K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
+6.8K
|
$2.12
|
+$14.32K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-136
|
$71.81
|
-$9.77K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-136
|
$71.81
|
-$9.77K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+8.7K
|
$50.04
|
+$434.25K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+343
|
$73.40
|
+$25.18K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+260
|
$73.40
|
+$19.08K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+289
|
$73.40
|
+$21.21K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+253
|
$73.40
|
+$18.57K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+1.6M
|
$72.43
|
+$115.56M
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-533
|
$65.40
|
-$34.86K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-389
|
$68.67
|
-$26.71K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+321
|
$68.78
|
+$22.08K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+244
|
$68.78
|
+$16.78K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+271
|
$68.78
|
+$18.64K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+237
|
$68.78
|
+$16.30K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+382
|
$65.36
|
+$24.97K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+1.4K
|
$73.21
|
+$99.27K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-388
|
$76.71
|
-$29.76K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-389
|
$77.49
|
-$30.14K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-4.9K
|
$78.29
|
-$384.48K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+5.6K
|
$18.69
|
+$104.48K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+27K
|
$23.82
|
+$633.92K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
+5.5K
|
$19.50
|
+$106.51K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
+4.5K
|
$25.01
|
+$112.49K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+5.6K
|
$18.69
|
+$104.48K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
+3.5K
|
$14.84
|
+$52.61K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
+4.5K
|
$25.03
|
+$112.51K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
+6.3K
|
$13.95
|
+$87.61K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+5.6K
|
$18.56
|
+$104.16K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-396
|
$84.09
|
-$33.30K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+283
|
$84.13
|
+$23.81K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+214
|
$84.13
|
+$18.00K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+238
|
$84.13
|
+$20.02K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+208
|
$84.13
|
+$17.50K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-50K
|
$85.48
|
-$4.27M
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-22K
|
$85.61
|
-$1.89M
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+255
|
$65.36
|
+$16.67K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-395
|
$84.13
|
-$33.23K
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+40K
|
$18.97
|
+$758.80K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-396
|
$85.40
|
-$33.82K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-517
|
$79.96
|
-$41.34K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-396
|
$81.57
|
-$32.30K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+298
|
$81.27
|
+$24.22K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+225
|
$81.27
|
+$18.29K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+251
|
$81.27
|
+$20.40K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+219
|
$81.27
|
+$17.80K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-20K
|
$81.08
|
-$1.62M
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$65.36
|
+$8.37K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-395
|
$79.73
|
-$31.49K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+13K
|
$77.37
|
+$1.00M
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
-1.2K
|
$84.99
|
-$102.84K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-395
|
$79.81
|
-$31.52K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-78
|
$100.50
|
-$7.84K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-2.7K
|
$100.00
|
-$274.40K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-1K
|
$87.35
|
-$87.35K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-78
|
$100.50
|
-$7.84K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
+5.6K
|
$2.75
|
+$15.36K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
+17K
|
$0.94
|
+$16.08K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-136
|
$86.45
|
-$11.76K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
-136
|
$86.45
|
-$11.76K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+275
|
$86.98
|
+$23.92K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+281
|
$86.98
|
+$24.44K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+213
|
$86.98
|
+$18.53K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+237
|
$86.98
|
+$20.61K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+207
|
$86.98
|
+$18.00K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$65.36
|
+$8.37K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-720
|
$82.05
|
-$59.08K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
-798
|
$83.00
|
-$66.23K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$81.10
|
+$10.38K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+254
|
$89.74
|
+$22.79K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+260
|
$89.74
|
+$23.33K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+197
|
$89.74
|
+$17.68K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+219
|
$89.74
|
+$19.65K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+187
|
$89.74
|
+$16.78K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$77.74
|
+$9.87K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
-20K
|
$94.51
|
-$1.89M
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$65.36
|
+$8.37K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-1.4K
|
$104.02
|
-$144.48K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-639
|
$104.25
|
-$66.62K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-2.4K
|
$104.25
|
-$252.29K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-626
|
$104.25
|
-$65.26K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-203
|
$104.25
|
-$21.16K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-639
|
$104.25
|
-$66.62K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
+2.4K
|
$65.42
|
+$158.25K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-3.6K
|
$108.06
|
-$388.48K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-15K
|
$109.52
|
-$1.62M
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+26K
|
$77.02
|
+$1.99M
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
+5.6K
|
$28.82
|
+$161.51K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+4.5K
|
$26.31
|
+$117.90K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
+4.6K
|
$25.03
|
+$115.64K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
+2.4K
|
$84.44
|
+$202.32K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+4.9K
|
$22.17
|
+$108.94K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
+2.9K
|
$16.97
|
+$48.60K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
+4.1K
|
$73.69
|
+$299.92K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+4.3K
|
$27.97
|
+$119.94K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+208
|
$103.97
|
+$21.63K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+229
|
$103.97
|
+$23.81K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+182
|
$103.97
|
+$18.92K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+202
|
$103.97
|
+$21.00K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+152
|
$103.97
|
+$15.80K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+199
|
$87.94
|
+$17.50K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
-9K
|
$105.31
|
-$947.79K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+2.6K
|
$0.08
|
+$205.28
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$65.36
|
+$8.37K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-19K
|
$89.78
|
-$1.69M
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-517
|
$86.81
|
-$44.88K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-1.8K
|
$85.00
|
-$156.57K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+784
|
$73.23
|
+$57.41K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+236
|
$73.23
|
+$17.28K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+327
|
$73.23
|
+$23.95K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+287
|
$73.23
|
+$21.02K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+243
|
$73.23
|
+$17.79K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+270
|
$73.23
|
+$19.77K
|
|
SEC
|
HARRIGAN EDMUND
|
N/A
|
|
+202
|
$73.23
|
+$14.79K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+128
|
$65.36
|
+$8.37K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+20K
|
$13.34
|
+$266.80K
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
+3.5K
|
$76.14
|
+$265.58K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Dickinson Jonathan Elliott
|
EVP, General Manager, Europe
|
|
+5.7K
|
$0.82
|
+$4.66K
|
|
SEC
|
Morrissey Michael James
|
EVP, Head of Tech. Operations
|
|
+5.7K
|
$0.82
|
+$4.66K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+127
|
$65.36
|
+$8.30K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-28K
|
$85.97
|
-$2.44M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+632
|
$87.32
|
+$55.19K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+190
|
$87.32
|
+$16.59K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+264
|
$87.32
|
+$23.05K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+231
|
$87.32
|
+$20.17K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+196
|
$87.32
|
+$17.11K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+218
|
$87.32
|
+$19.04K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+77
|
$65.36
|
+$5.03K
|
|
SEC
|
Dhanak Dashyant
|
EVP & Chief Scientific Officer
|
|
-533
|
$95.72
|
-$51.02K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+76
|
$65.36
|
+$4.97K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-50K
|
$3.90
|
-$195.00K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-930
|
$85.00
|
-$79.05K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+77
|
$65.36
|
+$5.03K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+728
|
$74.23
|
+$54.04K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+219
|
$74.23
|
+$16.26K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+304
|
$74.23
|
+$22.57K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+266
|
$74.23
|
+$19.75K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+225
|
$74.23
|
+$16.70K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+251
|
$74.23
|
+$18.63K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-2.5K
|
$77.71
|
-$193.58K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+76
|
$65.36
|
+$4.97K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+1.2K
|
$65.36
|
+$79.94K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
-1.7K
|
$85.07
|
-$146.66K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-959
|
$79.91
|
-$76.63K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-430
|
$81.39
|
-$35.00K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-2.4K
|
$81.39
|
-$195.34K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-409
|
$81.39
|
-$33.29K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-639
|
$73.31
|
-$46.85K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-291
|
$81.39
|
-$23.68K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-639
|
$81.39
|
-$52.01K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-273
|
$85.28
|
-$23.28K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-1.6K
|
$85.28
|
-$132.35K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-273
|
$85.28
|
-$23.28K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-267
|
$85.28
|
-$22.77K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-404
|
$85.28
|
-$34.45K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-148
|
$85.28
|
-$12.62K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-404
|
$85.28
|
-$34.45K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+6.3K
|
$4.94
|
+$31.34K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+37K
|
$4.87
|
+$181.35K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
+6.3K
|
$4.94
|
+$31.34K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
+6.3K
|
$5.53
|
+$34.79K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
+6.3K
|
$4.94
|
+$31.34K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+6.1K
|
$7.13
|
+$43.79K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
+3.4K
|
$6.96
|
+$23.90K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
+6.1K
|
$7.13
|
+$43.79K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+620
|
$84.96
|
+$52.68K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+195
|
$84.96
|
+$16.57K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+291
|
$84.96
|
+$24.72K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+237
|
$84.96
|
+$20.14K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+208
|
$84.96
|
+$17.67K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+203
|
$84.96
|
+$17.25K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-8.4K
|
$87.96
|
-$735.08K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-1.4K
|
$82.02
|
-$117.62K
|
|
SEC
|
Pasquale Maria E
|
EVP & General Counsel
|
|
-517
|
$82.73
|
-$42.77K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+660
|
$86.01
|
+$56.77K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+168
|
$86.01
|
+$14.45K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+276
|
$86.01
|
+$23.74K
|
|
SEC
|
Clancy Paul J
|
N/A
|
|
+203
|
$86.01
|
+$17.46K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+188
|
$86.01
|
+$16.17K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+145
|
$86.01
|
+$12.47K
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+40K
|
$2.80
|
+$112.00K
|
|
SEC
|
Stamoulis Christiana
|
EVP & Chief Financial Officer
|
|
+10K
|
$80.21
|
+$824.96K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1K
|
$80.00
|
-$80.00K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1.7K
|
$75.56
|
-$129.51K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-896
|
$74.21
|
-$66.49K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-4.6K
|
$74.21
|
-$341.66K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-847
|
$74.21
|
-$62.86K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-1.2K
|
$44.75
|
-$53.70K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-272
|
$46.80
|
-$12.73K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-808
|
$47.48
|
-$38.36K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-28K
|
$63.56
|
-$1.76M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+894
|
$63.59
|
+$56.85K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+228
|
$63.59
|
+$14.50K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+373
|
$63.59
|
+$23.72K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+255
|
$63.59
|
+$16.22K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+196
|
$63.59
|
+$12.46K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+1K
|
$68.77
|
+$68.77K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1K
|
$70.00
|
-$70.00K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+825
|
$69.08
|
+$56.99K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+209
|
$69.08
|
+$14.44K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+343
|
$69.08
|
+$23.69K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+235
|
$69.08
|
+$16.23K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+180
|
$69.08
|
+$12.43K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-430
|
$70.19
|
-$30.18K
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-455
|
$70.19
|
-$31.94K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-2.4K
|
$70.19
|
-$165.58K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-448
|
$70.19
|
-$31.45K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-577
|
$70.19
|
-$40.50K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-639
|
$70.19
|
-$44.85K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-196
|
$70.19
|
-$13.76K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-430
|
$70.19
|
-$30.18K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-606
|
$71.34
|
-$43.23K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-273
|
$68.28
|
-$18.64K
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-280
|
$68.28
|
-$19.12K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-1.5K
|
$68.28
|
-$104.60K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-284
|
$68.28
|
-$19.39K
|
|
SEC
|
Iyengar Vijay K
|
EVP GPS, BD, & Licensing
|
|
-273
|
$68.28
|
-$18.64K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-262
|
$68.28
|
-$17.89K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-404
|
$68.28
|
-$27.59K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
+2.6K
|
$2.47
|
+$6.40K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-273
|
$68.28
|
-$18.64K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+849
|
$67.00
|
+$56.88K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+216
|
$67.00
|
+$14.47K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+354
|
$0.59
|
+$208.86
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+242
|
$67.00
|
+$16.21K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+186
|
$67.00
|
+$12.46K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+20K
|
$2.80
|
+$56.00K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+60K
|
$9.92
|
+$595.20K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
+15K
|
$60.94
|
+$914.10K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+20K
|
$9.92
|
+$198.40K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+684
|
$83.33
|
+$57.00K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+174
|
$83.33
|
+$14.50K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+285
|
$83.33
|
+$23.75K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+195
|
$83.33
|
+$16.25K
|
|
SEC
|
FOUSE JACQUALYN A
|
N/A
|
|
+150
|
$83.33
|
+$12.50K
|
|
SEC
|
Stein Steven H
|
EVP & Chief Medical Officer
|
|
-2.1K
|
$86.61
|
-$180.24K
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-3K
|
$85.73
|
-$259.08K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-3K
|
$85.72
|
-$259.05K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-1K
|
$86.03
|
-$88.27K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-37K
|
$86.03
|
-$3.21M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-1K
|
$86.03
|
-$88.27K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-414
|
$86.03
|
-$35.62K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-1K
|
$86.03
|
-$88.27K
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-6.8K
|
$98.87
|
-$668.36K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+600
|
$94.71
|
+$56.83K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+153
|
$94.71
|
+$14.49K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+250
|
$94.71
|
+$23.68K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+171
|
$94.71
|
+$16.20K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-696
|
$98.01
|
-$68.21K
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-29K
|
$105.24
|
-$3.00M
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-7.8K
|
$106.79
|
-$835.95K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+486
|
$116.74
|
+$56.74K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+124
|
$116.74
|
+$14.48K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+203
|
$116.74
|
+$23.70K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+139
|
$116.74
|
+$16.23K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-71K
|
$119.45
|
-$8.42M
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-714
|
$124.25
|
-$88.71K
|
|
SEC
|
Baker Brothers Life Sciences LP
|
N/A
|
|
+100K
|
$132.00
|
+$13.20M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-1.8K
|
$137.40
|
-$250.07K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-20K
|
$140.00
|
-$2.80M
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-295
|
$74.07
|
-$21.85K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
+1.2K
|
$60.00
|
+$71.88K
|
|
SEC
|
Baker Brothers Life Sciences LP
|
N/A
|
|
+450
|
$125.91
|
+$56.66K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+115
|
$125.91
|
+$14.48K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+188
|
$125.91
|
+$23.67K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+129
|
$125.91
|
+$16.24K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
+1.3K
|
$66.66
|
+$86.12K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+500
|
$131.80
|
+$65.90K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+500
|
$115.00
|
+$57.50K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-16K
|
$121.96
|
-$1.99M
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
-4.4K
|
$125.00
|
-$551.63K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-5.3K
|
$124.73
|
-$660.57K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-1.8K
|
$124.73
|
-$227.01K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+500
|
$124.26
|
+$62.13K
|
|
SEC
|
GRYSKA DAVID W
|
Executive Vice President, CFO
|
|
-1.4K
|
$124.26
|
-$172.60K
|
|
SEC
|
Baker Brothers Life Sciences LP
|
N/A
|
|
+60K
|
$7.26
|
+$435.60K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+1K
|
$139.66
|
+$139.66K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+1K
|
$139.48
|
+$139.48K
|
|
SEC
|
Baker Brothers Life Sciences LP
|
N/A
|
|
+426
|
$133.67
|
+$56.94K
|
|
SEC
|
BIENAIME JEAN JACQUES
|
N/A
|
|
+108
|
$133.67
|
+$14.44K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+177
|
$133.67
|
+$23.66K
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+121
|
$133.67
|
+$16.17K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-2K
|
$131.88
|
-$264.82K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
+4.5K
|
$31.95
|
+$143.55K
|
|
SEC
|
Hoppenot Herve
|
Chairman / CEO
|
|
-23K
|
$85.53
|
-$2.01M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
+2.2K
|
$32.88
|
+$72.27K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+2.3K
|
$30.89
|
+$71.11K
|
|
SEC
|
Trower Paul
|
Principal Accounting Officer
|
|
-418
|
$121.95
|
-$50.98K
|
|
SEC
|
Wenqing Yao
|
EVP, Head of Discovery Chem
|
|
+1.5K
|
$30.90
|
+$47.40K
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-50K
|
$120.32
|
-$6.02M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-12K
|
$113.55
|
-$1.33M
|
|
SEC
|
Baker Brothers Life Sciences LP
|
N/A
|
|
+567
|
$100.27
|
+$56.85K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-10K
|
$103.26
|
-$1.03M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-2.7K
|
$109.95
|
-$298.51K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-10K
|
$90.00
|
-$900.00K
|
|
SEC
|
Flannelly Barry P
|
EVP & General Manager US
|
|
-24K
|
$97.00
|
-$2.35M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-12K
|
$96.40
|
-$1.13M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-20K
|
$90.00
|
-$1.80M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-10K
|
$87.96
|
-$879.60K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-60K
|
$90.00
|
-$5.40M
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+800K
|
$63.98
|
+$51.18M
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+64K
|
$70.79
|
+$4.55M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
+2K
|
$31.74
|
+$63.73K
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+887K
|
$69.87
|
+$61.99M
|
|
SEC
|
Baker Bros. Advisors (GP) LLC
|
N/A
|
|
+2.3M
|
$63.53
|
+$143.03M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-14K
|
$76.96
|
-$1.04M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$101.86
|
-$401.02K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-1.9K
|
$107.96
|
-$209.01K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$106.18
|
-$418.03K
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-225K
|
$113.83
|
-$25.61M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$104.86
|
-$233.00K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$116.51
|
-$458.58K
|
|
SEC
|
Wenqing Yao
|
EVP, Discovery Medicinal and P
|
|
-5.8K
|
$124.78
|
-$721.98K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$101.49
|
-$225.51K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$122.29
|
-$481.46K
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-10K
|
$124.29
|
-$1.24M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$130.69
|
-$290.39K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-4.3K
|
$130.00
|
-$559.13K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$118.90
|
-$468.11K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$107.69
|
-$239.29K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$111.95
|
-$440.64K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-70K
|
$120.00
|
-$8.43M
|
|
SEC
|
Wenqing Yao
|
EVP, Discovery Medicinal and P
|
|
-13K
|
$116.70
|
-$1.50M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$113.61
|
-$252.44K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$107.00
|
-$421.26K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-12K
|
$108.24
|
-$1.27M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-20K
|
$108.13
|
-$2.16M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$105.31
|
-$234.10K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-3.9K
|
$107.58
|
-$423.54K
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-197K
|
$107.23
|
-$21.10M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-12K
|
$106.40
|
-$1.29M
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-102K
|
$108.22
|
-$11.06M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$104.99
|
-$233.29K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-7.4K
|
$99.43
|
-$736.98K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-37K
|
$107.67
|
-$3.98M
|
|
SEC
|
Wenqing Yao
|
EVP, Discovery Medicinal and P
|
|
-7.2K
|
$102.04
|
-$729.59K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$98.72
|
-$219.36K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-16K
|
$96.29
|
-$1.59M
|
|
SEC
|
Wenqing Yao
|
EVP, Discovery Medicinal and P
|
|
-23K
|
$95.18
|
-$2.19M
|
|
SEC
|
Wenqing Yao
|
EVP, Discovery Medicinal and P
|
|
-20K
|
$90.13
|
-$1.81M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-25K
|
$88.77
|
-$2.22M
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-114K
|
$93.64
|
-$10.65M
|
|
SEC
|
Huber Reid M
|
EVP, Chief Scientific Officer
|
|
-34K
|
$93.66
|
-$3.21M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-18K
|
$89.97
|
-$1.57M
|
|
SEC
|
ARIKO BARRY A
|
N/A
|
|
-80K
|
$89.27
|
-$7.14M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-2.2K
|
$89.71
|
-$199.34K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev Officer
|
|
-25K
|
$89.91
|
-$2.25M
|
|
SEC
|
DE SCHUTTER RICHARD U
|
N/A
|
|
-40K
|
$92.09
|
-$3.68M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-13K
|
$90.00
|
-$1.20M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-13K
|
$85.00
|
-$1.13M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$82.19
|
-$913.30K
|
|
SEC
|
ARIKO BARRY A
|
N/A
|
|
-20K
|
$78.43
|
-$1.57M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-12K
|
$76.90
|
-$922.80K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-18K
|
$76.90
|
-$1.35M
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-120K
|
$74.32
|
-$8.92M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-25K
|
$75.11
|
-$1.88M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-14K
|
$79.85
|
-$1.08M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$77.68
|
-$862.95K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-18K
|
$74.17
|
-$1.30M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-12K
|
$73.07
|
-$876.84K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-16K
|
$75.00
|
-$1.17M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-25K
|
$71.84
|
-$1.80M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-18K
|
$73.90
|
-$1.29M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$74.43
|
-$827.14K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-12K
|
$72.36
|
-$868.32K
|
|
SEC
|
DE SCHUTTER RICHARD U
|
N/A
|
|
-50K
|
$74.89
|
-$3.74M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$74.08
|
-$823.10K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-12K
|
$69.97
|
-$839.64K
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-186K
|
$67.87
|
-$12.60M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$53.49
|
-$594.33K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$49.03
|
-$392.24K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$47.65
|
-$529.44K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$47.58
|
-$380.64K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$51.96
|
-$577.33K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$51.97
|
-$415.76K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$48.54
|
-$539.33K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$48.15
|
-$385.20K
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$56.03
|
-$622.55K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$53.88
|
-$431.04K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
-200K
|
$52.73
|
-$10.55M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-11K
|
$48.48
|
-$538.66K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-8K
|
$50.68
|
-$405.44K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-2.1K
|
$54.00
|
-$111.13K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-34K
|
$51.55
|
-$1.75M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-31K
|
$47.71
|
-$1.46M
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-33K
|
$63.51
|
-$2.12M
|
|
SEC
|
DE SCHUTTER RICHARD U
|
N/A
|
|
-50K
|
$65.53
|
-$3.28M
|
|
SEC
|
FRIEDMAN PAUL A
|
N/A
|
|
-771K
|
$65.65
|
-$50.63M
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
-275K
|
$65.86
|
-$18.11M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-231K
|
$66.34
|
-$15.33M
|
|
SEC
|
ARIKO BARRY A
|
N/A
|
|
-10K
|
$66.49
|
-$664.90K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-98K
|
$66.28
|
-$6.52M
|
|
SEC
|
Daly James M
|
EVP, Chief Commercial Officer
|
|
-158K
|
$66.49
|
-$10.53M
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-56K
|
$66.67
|
-$3.74M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-217K
|
$66.73
|
-$14.48M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-50K
|
$47.37
|
-$2.37M
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
-377K
|
$37.32
|
-$14.06M
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-45K
|
$37.31
|
-$1.67M
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
-100K
|
$35.16
|
-$3.52M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-25K
|
$35.28
|
-$882.00K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-56K
|
$35.17
|
-$1.97M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-94K
|
$35.06
|
-$3.31M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-50K
|
$26.70
|
-$1.34M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-40K
|
$23.08
|
-$923.20K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-56K
|
$22.30
|
-$1.24M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-10K
|
$25.08
|
-$250.80K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-10K
|
$22.56
|
-$225.60K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-50K
|
$22.16
|
-$1.11M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+103K
|
$21.53
|
+$2.22M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-30K
|
$21.82
|
-$654.60K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
-100K
|
$22.52
|
-$2.25M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-98K
|
$22.48
|
-$2.21M
|
|
SEC
|
DE SCHUTTER RICHARD U
|
N/A
|
|
-5K
|
$16.07
|
-$80.35K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-36K
|
$25.11
|
-$896.43K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-37K
|
$24.15
|
-$885.48K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$22.27
|
-$445.40K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
-5K
|
$23.55
|
-$117.75K
|
|
SEC
|
Siegel Eric H.
|
EVP, General Counsel
|
|
-57K
|
$23.12
|
-$1.33M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-147K
|
$23.22
|
-$3.42M
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
-225K
|
$22.56
|
-$5.08M
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-14K
|
$22.70
|
-$317.26K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-30K
|
$22.95
|
-$688.50K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$17.53
|
-$350.60K
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+50K
|
$17.70
|
+$885.00K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+558K
|
$16.37
|
+$9.13M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+414K
|
$13.37
|
+$5.54M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+1.6M
|
$13.75
|
+$21.96M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+2.5M
|
$13.13
|
+$32.27M
|
|
SEC
|
DIXON WENDY L
|
N/A
|
|
+7.5K
|
$13.40
|
+$100.50K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-40K
|
$18.61
|
-$744.40K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$18.02
|
-$360.40K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
-100K
|
$17.74
|
-$1.77M
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-75K
|
$19.30
|
-$1.45M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$20.16
|
-$403.20K
|
|
SEC
|
SCHRECK PATRICIA A
|
EVP, General Counsel
|
|
-100K
|
$20.24
|
-$2.02M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$19.51
|
-$390.20K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-5.3K
|
$19.55
|
-$104.46K
|
|
SEC
|
METCALF BRIAN W
|
Chief Drug Discovery Scientist
|
|
-100K
|
$17.41
|
-$1.74M
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-25K
|
$17.01
|
-$425.25K
|
|
SEC
|
SCHRECK PATRICIA A
|
EVP, General Counsel
|
|
-100K
|
$16.50
|
-$1.65M
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-10K
|
$16.01
|
-$160.10K
|
|
SEC
|
METCALF BRIAN W
|
Chief Drug Discovery Scientist
|
|
-210K
|
$14.26
|
-$2.99M
|
|
SEC
|
METCALF BRIAN W
|
Chief Drug Discovery Scientist
|
|
-50K
|
$14.35
|
-$717.50K
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-40K
|
$15.80
|
-$636.90K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-20K
|
$17.01
|
-$340.20K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-11K
|
$15.99
|
-$175.89K
|
|
SEC
|
WHITFIELD ROY A
|
N/A
|
|
-34K
|
$16.97
|
-$581.27K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
-1.5M
|
$14.88
|
-$22.32M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
-593K
|
$14.06
|
-$8.34M
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
-16K
|
$14.06
|
-$219.59K
|
|
SEC
|
SCHRECK PATRICIA A
|
EVP, General Counsel
|
|
-95K
|
$13.88
|
-$1.32M
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+10K
|
$10.43
|
+$104.30K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
+2K
|
$10.24
|
+$20.48K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
-98K
|
$13.15
|
-$1.29M
|
|
SEC
|
Levy Richard S
|
EVP, Chief Drug Dev&Medical Of
|
|
-20K
|
$12.94
|
-$258.80K
|
|
SEC
|
Friedman Steven M.
|
EVP, Biology & Preclinical Dev
|
|
-22K
|
$10.90
|
-$239.80K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+20K
|
$2.10
|
+$42.00K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+25K
|
$2.15
|
+$53.64K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+20K
|
$2.20
|
+$44.00K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+42K
|
$2.15
|
+$91.06K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+990K
|
$3.51
|
+$3.47M
|
|
SEC
|
METCALF BRIAN W
|
Chief Drug Discovery Scientist
|
|
+5K
|
$2.19
|
+$10.95K
|
|
SEC
|
Chardonnet Laurent
|
N/A
|
|
+8K
|
$2.71
|
+$21.68K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+13K
|
$2.55
|
+$33.15K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
+4K
|
$2.36
|
+$9.44K
|
|
SEC
|
SCHRECK PATRICIA A
|
EVP, General Counsel
|
|
+2.5K
|
$2.44
|
+$6.10K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+1.1M
|
$9.00
|
+$9.90M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+300
|
$10.62
|
+$3.19K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+50K
|
$10.99
|
+$551.85K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+178K
|
$10.94
|
+$1.94M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+1.4M
|
$10.14
|
+$14.62M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+345K
|
$10.60
|
+$3.65M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+629K
|
$9.99
|
+$6.28M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+80K
|
$8.98
|
+$718.40K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+117K
|
$8.68
|
+$1.01M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+499K
|
$8.11
|
+$4.05M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+359K
|
$8.17
|
+$2.93M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+318
|
$8.22
|
+$2.61K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+475K
|
$8.49
|
+$4.03M
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+994K
|
$8.09
|
+$8.04M
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+17K
|
$5.47
|
+$91.16K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+639K
|
$4.91
|
+$3.14M
|
|
SEC
|
METCALF BRIAN W
|
Chief Drug Discovery Scientist
|
|
+5K
|
$3.88
|
+$19.40K
|
|
SEC
|
SWAIN PAULA J
|
EVP, Human Resources
|
|
+3K
|
$3.65
|
+$10.95K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+5.5K
|
$3.56
|
+$19.58K
|
|
SEC
|
HASTINGS DAVID C
|
Chief Financial Officer
|
|
+2.5K
|
$3.60
|
+$9.00K
|
|
SEC
|
SCHRECK PATRICIA A
|
EVP, General Counsel
|
|
+2K
|
$3.59
|
+$7.18K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+2.7K
|
$7.24
|
+$19.55K
|
|
SEC
|
BAKER JULIAN
|
N/A
|
|
+300K
|
$9.75
|
+$2.93M
|
|
SEC
|
BROOKE PAUL A
|
N/A
|
|
+100K
|
$7.74
|
+$774.00K
|
|
SEC
|
FRIEDMAN PAUL A
|
Chief Executive Officer
|
|
+3.5K
|
$5.62
|
+$19.67K
|
|
SEC
|
TISCH ANDREW H
|
N/A
|
|
+256K
|
$5.50
|
+$1.41M
|
|
SEC
|
TISCH DANIEL R
|
N/A
|
|
+256K
|
$5.50
|
+$1.41M
|
|
SEC
|
TISCH JAMES S
|
N/A
|
|
+256K
|
$5.50
|
+$1.41M
|
|
SEC
|
TISCH THOMAS J
|
N/A
|
|
+256K
|
$5.50
|
+$1.41M
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+152K
|
$4.97
|
+$756.43K
|
|
SEC
|
BAKER FELIX
|
N/A
|
|
+1.2M
|
$5.04
|
+$6.00M
|
|